Dose‐finding approach for dose escalation with overdose control considering incomplete observations
- 24 February 2011
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 30 (13), 1584-1594
- https://doi.org/10.1002/sim.4128
Abstract
We propose a hybrid design, the time‐to‐event dose‐escalation method with overdose control (TITE‐EWOC), introducing the time‐to‐event approach, developed by Cheungit et al., in the EWOC method, developed by Babb et al. The aim of this new design is to decrease the dose‐finding trial duration, without impairing the characteristics of the EWOC design, especially the overdose control ability. We conducted a simulation study, exploring four dose–toxicity relationships and three mean inter‐patient arrival times. Performances of TITE‐EWOC were compared with those of the EWOC method. This study shows that the trial duration can be greatly decreased with the TITE‐EWOC, without impacting the proportion of overdosed patients or the number of dose‐limiting toxicities by trial, for all explored dose–toxicity relationships, except for very short inter‐patient arrival times. The ability of the method to find the true maximum tolerated dose remains unchanged. Copyright © 2011 John Wiley & Sons, Ltd.Keywords
This publication has 12 references indexed in Scilit:
- Unifying CRM and EWOC designs for phase I cancer clinical trialsJournal of Statistical Planning and Inference, 2009
- Dose escalation of oral vinorelbine in combination with estramustine in hormone‐refractory adenocarcinoma of the prostateCancer, 2006
- Generalizing the TITE‐CRM to adapt for early‐ and late‐onset toxicitiesStatistics in Medicine, 2005
- Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose controlStatistics in Medicine, 2005
- Individualized Patient Dosing in Phase I Clinical Trials: The Role of Escalation With Overdose Control in PNU-214936Journal of Clinical Oncology, 2004
- Phase I Trial Using a Time-to-Event Continual Reassessment Strategy for Dose Escalation of Cisplatin Combined With Gemcitabine and Radiation Therapy in Pancreatic CancerJournal of Clinical Oncology, 2004
- Patient specific dosing in a cancer phase I clinical trialStatistics in Medicine, 2001
- Sequential Designs for Phase I Clinical Trials with Late‐Onset ToxicitiesBiometrics, 2000
- Some practical improvements in the continual reassessment method for phase I studiesStatistics in Medicine, 1995